COMMUNIQUÉS West-GlobeNewswire

Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation
27/04/2026
Positive clinical results from Alcohol Use Disorder clinical trial may strengthen potential for eligibility for Breakthrough Therapy Designation Vancouver, Canada, April 27, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine [...]
Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy
27/04/2026
– Alignment reached on chemistry, manufacturing, and control (CMC) elements of ATH434 Phase 3 development program – – Positive feedback supports readiness for Phase 3 initiation with manufacturing scale-up progressing [...]
Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700
27/04/2026
-- Company’s extended-release formulation of zinc acetate will be compared to GALZIN® (zinc acetate) and a placebo for the treatment of Wilson disease -- DEER PARK, Ill., April 27, 2026 (GLOBE NEWSWIRE) -- Eton [...]
Ocular Therapeutix™ to Participate in May Scientific and Investor Conferences
27/04/2026
BEDFORD, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation [...]
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026
27/04/2026
― Presented positive clinical data for pociredir, demonstrating robust and rapid fetal hemoglobin (HbF) induction, improvements in markers of hemolysis and anemia, and encouraging trends in vaso-occlusive crisis (VOC) [...]
Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis
27/04/2026
Topline data is on track for anticipated readout in the summer of 2026 WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission [...]
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
27/04/2026
Transaction expands Ligand’s royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand’s long-term compounding growth, adding a complementary portfolio across [...]
Every minute counts: EAACI calls for urgent action to make schools safe for children at risk of anaphylaxis
27/04/2026
At the Spanish Congress of Deputies, EAACI President María José Torres backed a joint manifesto with AEPNAA, SEAIC, and SEICAP, calling for urgent action on school protocols, staff training, and access to life-saving [...]
Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer
27/04/2026
Zovegalisib + atirmociclib + AI selected as triplet regimen for frontline development Compelling efficacy and tolerability data for zovegalisib triplet in median 3L patients 44% ORR in heavily pre-treated, CDK4/6- [...]
HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors
27/04/2026
Its lead T-Cell Engager HCW11-018b is shown to penetrate into the tumor microenvironment with potent and antigen-specific anti-pancreatic cancer activities IND application expected to be filed in first half of 2027 to [...]
Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock
27/04/2026
SAN MATEO, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic [...]
Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities
27/04/2026
$225 million funded at closing, with an additional $225 million warrant tranche Financing funds operations through anticipated Phase 3 MASH 52-week data readout Financing was led by Deep Track Capital, with [...]
Composition of the Nomination Committee of Orion Corporation
27/04/2026
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 27 APRIL 2026 at 12:00 EEST Composition of the Nomination Committee of Orion Corporation The Board of [...]
Seer Board of Directors Unanimously Rejects Revised Unsolicited Proposal from Radoff-JEC Group
27/04/2026
Board Determines Proposal Significantly Undervalues Seer and Is Not in the Best Interests of Stockholders REDWOOD CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the [...]
BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026
27/04/2026
CARSON CITY, Nev., April 27, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases [...]
Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis
27/04/2026
ORKA-001 achieved 63.5% (40/63) PASI 100 at Week 16 Favorable safety profile consistent with the IL-23p19 class Updated Phase 1 PK/PD data continue to support the potential for once-yearly dosing, with longer-term [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
27/04/2026
COPENHAGEN, Denmark, April 27, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on March 12, 2026, under which the Company will repurchase shares for an amount up [...]
AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Research
27/04/2026
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, [...]
Novo Nordisk A/S - share repurchase programme
27/04/2026
Bagsværd, Denmark, 27 April 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]

Pages